Loading
HKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$2.45
+HK$0.04 · +1.66%
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
Latest quote
HK$2.45
+HK$0.04 · +1.66%
Regular session · HKT · Market data may be delayed.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
Day range
Current HK$2.45
52-week range
Current HK$2.45
Regular session · HKT · Market data may be delayed.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
Day range
Current HK$2.45
52-week range
Current HK$2.45
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 480.18M CNY | 255.89M CNY | 76.61M CNY | 17.6M CNY | — |
| Cost of goods sold | 207.08M CNY | 131.17M CNY | 39.24M CNY | 9.91M CNY | 38.48M CNY |
| Gross profit | 273.1M CNY | 124.72M CNY | 37.37M CNY | 7.69M CNY | −38.48M CNY |
| Research and development | 141.56M CNY | 215.09M CNY | 171.54M CNY | 129.53M CNY | 186.84M CNY |
| Selling, general, and administrative | 279.92M CNY | 269.94M CNY | 203.9M CNY | 145.28M CNY | 134.84M CNY |
| Operating expenses | 414.23M CNY | 477.37M CNY | 375.44M CNY | 274.81M CNY | 321.67M CNY |
| Interest income | 11.19M CNY | 13.44M CNY | 16.51M CNY | 4.24M CNY | 5.04M CNY |
| Interest expense | 7.94M CNY | 8.61M CNY | 7.91M CNY | 3.67M CNY | 3.95M CNY |
| Depreciation and amortization | 31.63M CNY | 14.94M CNY | 36.24M CNY | 31.78M CNY | 11.98M CNY |
| Operating income | −141.13M CNY | −352.64M CNY | −289.09M CNY | −267.12M CNY | −320.52M CNY |
| Net income | 1.08B CNY | −250.14M CNY | −211.23M CNY | −203.77M CNY | −330.95M CNY |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Emerging Markets ETFSPEM614.01K0.00%17.86B USD0.07%$52.51+0.67%
Avantis Emerging Markets Equity ETFAVEM291.5K—28.6B USD0.33%$95.35+1.29%
Avantis Emerging Markets Value ETFAVES174.69K0.01%1.55B USD0.36%$66.29+1.16%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX91.44K0.01%684.6M USD0.65%$72.61+0.30%
Dimensional World ex U.S. Core Equity 2 ETFDFAX54.86K0.00%12.61B USD0.28%$38.06+0.95%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM43.95K0.00%9.62B USD0.39%$40.53+1.12%
Dimensional - Emerging Core Equity Market ETFDFAE43.8K0.00%10.17B USD0.29%$40.13+1.24%
State Street SPDR S&P China ETFGXC31.2K0.01%469.71M USD0.59%$87.58-0.21%State Street SPDR Portfolio Emerging Markets ETFSPEMAvantis Emerging Markets Equity ETFAVEMAvantis Emerging Markets Value ETFAVESState Street SPDR S&P Emerging Markets Small Cap ETFEWXDimensional World ex U.S. Core Equity 2 ETFDFAXDimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEState Street SPDR S&P China ETFGXCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
